Colorectal cancer (CRC) ranks as the third most commonly diagnosed malignancy globally and the second leading cause of cancer-related deaths [1]. Although traditionally considered a disease of the elderly, recent trends indicate a rising incidence among younger adults, especially in developing nations [2]. The pathogenesis of CRC is complex and multifactorial, involving environmental influences, lifestyle factors, and genetic predispositions. Global incidence patterns reveal wide geographical disparities. Developed regions such as North America, Western Europe, and Australia report higher incidence rates, whereas Africa and parts of Asia, including India, have comparatively lower but steadily rising rates [3]. Factors such as westernized diets, sedentary lifestyles, obesity, and smoking contribute significantly to this epidemiological shift. A detailed understanding of the clinicopathological features of CRC—including age and gender distribution, tumor location, histological subtypes, and staging—is critical to improving diagnostic accuracy and patient outcomes.

A narrative review was conducted using PubMed, Scopus, and Web of Science databases. Keywords such as “colorectal cancer,” “clinicopathological correlation,” “CRC staging,” “CRC risk factors,” and “colorectal histopathology” were used. Inclusion criteria comprised English-language articles published between 2016 and 2024 focusing on human subjects. Studies addressing epidemiology, risk factors, histology, tumor staging, and clinical outcomes were prioritized. Data were synthesized qualitatively to provide an updated and comprehensive overview.

Demographics

CRC shows a slight male predominance with a male-to-female ratio of approximately 1.2–1.5:1 [4]. The majority of CRCs are diagnosed after the age of 50, but early-onset cases (<50 years) are increasingly recognized, particularly in high-income and urbanizing countries [5].  In India, the median age of CRC diagnosis is lower than Western populations, with many cases occurring in the fourth and fifth decades of life [6].

Risk Factors

Lifestyle factors play a dominant role in CRC etiology. High intake of red and processed meats, low fiber diets, obesity, physical inactivity, smoking, and heavy alcohol consumption are associated with increased risk [7]. Genetic syndromes like Lynch syndrome and familial adenomatous polyposis (FAP) account for 5-10% of cases [8]. Chronic inflammatory conditions, such as ulcerative colitis and Crohn’s disease, also predispose individuals to CRC [9].

Clinical Presentation

The presenting symptoms vary depending on tumor location. Right-sided colon cancers often present with anemia, fatigue, and occult bleeding, while left-sided tumors typically cause changes in bowel habits, rectal bleeding, and obstruction [10]. Acute presentations such as bowel perforation or obstruction occur in approximately 15–20% of cases and are associated with poorer outcomes [11].

Histopathological Features

The vast majority (>90%) of CRCs are adenocarcinomas, which are classified based on the degree of glandular differentiation [12]. Subtypes include mucinous adenocarcinoma (characterized by abundant extracellular mucin) and signet ring cell carcinoma, both associated with poorer prognosis [13]. Microsatellite instability (MSI) and chromosomal instability are the two major molecular pathways implicated in CRC carcinogenesis [14].

Tumor Staging

CRC staging follows the TNM (Tumor-Node-Metastasis) classification. Early-stage disease (Stages I and II) has favorable prognoses with five-year survival rates exceeding 70%, whereas advanced stages (Stages III and IV) are associated with significantly reduced survival [15]. Distant metastasis commonly involves the liver, lungs, and peritoneum. Accurate staging requires histopathological assessment of resected specimens and appropriate imaging modalities [16].

The clinicopathological profile of CRC is undergoing notable transitions. Increasing incidence among younger adults and variations in tumor biology pose diagnostic and therapeutic challenges. Traditional risk factors remain pivotal, but emerging genetic and molecular markers provide new insights into tumor behavior and prognosis.

Early-onset CRC often exhibits more aggressive histopathological features, including poor differentiation, mucinous or signet ring histology, and advanced stage at diagnosis [5,13]. This highlights the need for revised screening guidelines and heightened clinical suspicion in younger populations.

Despite improvements in imaging and minimally invasive surgical techniques, outcomes for metastatic CRC remain suboptimal. Multimodal treatment strategies combining surgery, chemotherapy, targeted therapies, and immunotherapy are crucial for improving survival.

The role of histopathology extends beyond diagnosis to guide personalized therapy. The identification of MSI-high tumors has therapeutic implications, including eligibility for immune checkpoint inhibitors [14].

Public health initiatives focusing on modifiable risk factors—such as dietary modifications, physical activity promotion, smoking cessation, and alcohol moderation—are essential components of CRC prevention strategies.

Colorectal cancer presents a dynamic clinicopathological profile influenced by demographic, environmental, and molecular factors. Understanding these trends is essential for developing targeted prevention, early detection, and treatment strategies. Future efforts should emphasize early diagnosis, molecular profiling, and personalized therapeutic approaches to optimize outcomes across diverse populations.

1. Bray, F., et al. "Global Cancer Statistics 2018: GLOBOCAN Estimates." CA: A Cancer Journal for Clinicians, vol. 68, no. 6, 2018, pp. 394–424.

2. Siegel, R.L., et al. "Colorectal Cancer Rising in Young Adults: Epidemiology, Risk Factors, and Prevention Strategies." Nature Reviews Clinical Oncology, vol. 16, no. 12, 2019, pp. 713–732.

3. Arnold, M., et al. "Global Patterns and Trends in Colorectal Cancer Incidence and Mortality." Gut, vol. 66, no. 4, 2017, pp. 683–691.

4. Brenner, H., et al. "Colorectal Cancer." The Lancet, vol. 383, no. 9927, 2014, pp. 1490–1502.

5. Vuik, F.E., et al. "Increasing Incidence of Colorectal Cancer in Young Adults." Gut, vol. 68, no. 10, 2019, pp. 1820–1826.

6. Rajaraman, S., et al. "Rising Burden of Colorectal Cancer in India: An Epidemiological Perspective." Indian Journal of Gastroenterology, vol. 39, no. 3, 2020, pp. 195–200.

7. World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Colorectal Cancer Report 2018.

8. Stoffel, E.M., et al. "Hereditary Colorectal Cancer Syndromes: Updated Guidelines." Journal of the National Comprehensive Cancer Network, vol. 17, no. 9, 2019, pp. 1032–1041.

9. Jess, T., et al. "Risk of Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis." Clinical Gastroenterology and Hepatology, vol. 10, no. 6, 2012, pp. 639–645.

10. Hamilton, W., et al. "Symptoms and Diagnostic Delay in Colorectal Cancer: A Review." British Journal of Cancer, vol. 115, no. 5, 2016, pp. 553–558.

11. Sjo, O.H., et al. "Acute Presentation of Colorectal Cancer: Factors Predicting Surgical Outcome." Colorectal Disease, vol. 11, no. 7, 2009, pp. 688–695.

12. Hamilton, S.R., et al. WHO Classification of Tumours: Digestive System Tumours. 5th ed., IARC, 2019

13. Bosman, F.T., et al. "Mucinous and Signet-Ring Cell Colorectal Carcinomas: Clinicopathological Significance." Histopathology, vol. 68, no. 6, 2016, pp. 1005–1014.

14. Sinicrope, F.A. "Lynch Syndrome-Associated Colorectal Cancer." New England Journal of Medicine, vol. 379, no. 8, 2018, pp. 764–773.

15. Amin, M.B., et al. AJCC Cancer Staging Manual. 8th ed., Springer, 2017.

16. Schmoll, H.J., et al. "ESMO Consensus Guidelines for Management of Patients with Metastatic Colorectal Cancer." Annals of Oncology, vol. 27, no. 8, 2016, pp. 1386–1422